RESUMO
The cannabinoid receptor CB2 is predominately expressed in the immune system, and selective modulation of CB2 without the psychoactivity of CB1 has therapeutic potential in inflammatory, fibrotic, and neurodegenerative diseases. Here, we report the crystal structure of human CB2 in complex with a rationally designed antagonist, AM10257, at 2.8 Å resolution. The CB2-AM10257 structure reveals a distinctly different binding pose compared with CB1. However, the extracellular portion of the antagonist-bound CB2 shares a high degree of conformational similarity with the agonist-bound CB1, which led to the discovery of AM10257's unexpected opposing functional profile of CB2 antagonism versus CB1 agonism. Further structural analysis using mutagenesis studies and molecular docking revealed the molecular basis of their function and selectivity for CB2 and CB1. Additional analyses of our designed antagonist and agonist pairs provide important insight into the activation mechanism of CB2. The present findings should facilitate rational drug design toward precise modulation of the endocannabinoid system.
Assuntos
Receptor CB2 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/ultraestrutura , Animais , Antagonistas de Receptores de Canabinoides/farmacologia , Canabinoides/farmacologia , Desenho de Fármacos , Endocanabinoides , Humanos , Ligantes , Simulação de Acoplamento Molecular , Ligação Proteica , Receptor CB1 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/química , Receptores de Canabinoides/química , Receptores de Canabinoides/metabolismo , Receptores de Canabinoides/ultraestrutura , Receptores Acoplados a Proteínas G/metabolismo , Células Sf9 , Relação Estrutura-AtividadeRESUMO
The reason why neurons synthesize more than one endocannabinoid (eCB) and how this is involved in the regulation of synaptic plasticity in a single neuron is not known. We found that 2-arachidonoylglycerol (2-AG) and anandamide mediate different forms of plasticity in the extended amygdala of rats. Dendritic L-type Ca(2+) channels and the subsequent release of 2-AG acting on presynaptic CB1 receptors triggered retrograde short-term depression. Long-term depression was mediated by postsynaptic mGluR5-dependent release of anandamide acting on postsynaptic TRPV1 receptors. In contrast, 2-AG/CB1R-mediated retrograde signaling mediated both forms of plasticity in the striatum. These data illustrate how the eCB system can function as a polymodal signal integrator to allow the diversification of synaptic plasticity in a single neuron.
Assuntos
Moduladores de Receptores de Canabinoides/metabolismo , Endocanabinoides , Neurônios/fisiologia , Núcleos Septais/citologia , Núcleos Septais/metabolismo , Transdução de Sinais/fisiologia , Animais , Ácidos Araquidônicos/metabolismo , Biofísica , Cálcio/metabolismo , Bloqueadores dos Canais de Cálcio/farmacologia , Canais de Cálcio Tipo L/metabolismo , Canais de Cálcio Tipo L/ultraestrutura , Moduladores de Receptores de Canabinoides/farmacologia , Cromonas/farmacologia , Cicloexanonas/farmacologia , Estimulação Elétrica , Inibidores Enzimáticos/farmacologia , Antagonistas de Aminoácidos Excitatórios/farmacologia , Glicerídeos/metabolismo , Técnicas In Vitro , Depressão Sináptica de Longo Prazo/efeitos dos fármacos , Depressão Sináptica de Longo Prazo/fisiologia , Neurônios/efeitos dos fármacos , Neurônios/ultraestrutura , Nimodipina/farmacologia , Técnicas de Patch-Clamp , Piperidinas/farmacologia , Pirazóis/farmacologia , Piridinas/farmacologia , Ratos , Ratos Sprague-Dawley , Receptor CB2 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/ultraestrutura , Receptor de Glutamato Metabotrópico 5 , Receptores de Glutamato Metabotrópico/metabolismo , Receptores de Glutamato Metabotrópico/ultraestrutura , Transdução de Sinais/efeitos dos fármacos , Sinapses/metabolismo , Sinapses/ultraestrutura , Canais de Cátion TRPV/metabolismo , Canais de Cátion TRPV/ultraestrutura , Fatores de TempoRESUMO
The expression of CB2 cannabinoid receptors (CB2-Rs) in the brain and their neuronal function has now attracted research interest, since we and others have demonstrated the presence of CB2-Rs in neuronal and glial cells in the brain. In this study, we show the subcellular distribution of CB2-Rs in neuronal, glial, and endothelial cells in the rat hippocampus using immunohistochemical electron microscopy. Brain sections from the hippocampus were immunolabeled for CB2-R, visualized, and analyzed by electron microscopy. We found that in neurons, CB2-R immunoreactivity is present in the cell body as well as in large and medium-sized dendrites. In the soma, the CB2-R labeling is associated with the rough endoplasmic reticulum and Golgi apparatus demonstrating that CB2-Rs are synthesized by hippocampal neurons. CB2-R labeling in dendrites was observed in the cytoplasm and associated with the plasma membrane near the area of synaptic contact with axon terminals indicating a postsynaptic distribution of these receptors. In CB2-R immunoreactive glial and endothelial cells, the labeling was also found to be associated with the plasma membrane. These results provide the first ultrastructural evidence that CB2-Rs are mainly postsynaptic in the rat hippocampus.
Assuntos
Hipocampo/química , Hipocampo/ultraestrutura , Receptor CB2 de Canabinoide/metabolismo , Receptor CB2 de Canabinoide/ultraestrutura , Membranas Sinápticas/química , Membranas Sinápticas/ultraestrutura , Sequência de Aminoácidos , Animais , Potenciais Pós-Sinápticos Excitadores/fisiologia , Hipocampo/metabolismo , Masculino , Microscopia Imunoeletrônica , Dados de Sequência Molecular , Ratos , Ratos Sprague-DawleyRESUMO
For over a decade, until recently, it was thought that marijuana acts by activating brain-type cannabinoid receptors called CB1, and that a second type called CB2 cannabinoid receptor was found only in peripheral tissues. Neuronal CB2 receptors in the brain had been controversial. We reported the discovery and functional presence of CB2 cannabinoid receptors in the mammalian brain that may be involved in depression and drug abuse and this was supported by reports of identification of neuronal CB2 receptors that are involved in emesis. RT-PCR, immunoblotting, hippocampal cultures, immunohistochemistry, transmission electron microscopy, and stereotaxic techniques with behavioral assays were used to determine the functional expression of CB2 cannabinoid receptors in the rat brain and mouse brain exposed to chronic mild stress or treated with abused drugs. RT-PCR analyses supported the expression of brain CB2 receptor transcripts at levels much lower than those of CB1 receptors. In situ hybridization revealed CB2 mRNA in cerebellar neurons of wild-type but not of CB2 knockout mice. Abundant CB2 receptor immunoreactivity (iCB2) in neuronal and glial processes was detected in the brain. The effect of direct CB2 antisense oligonucleotide injection into the brain and treatment with JWH015 in motor function and plus-maze tests also demonstrated the functional presence of CB2 cannabinoid receptors in the central nervous system. In humans, there was a high incidence of Q63R polymorphism in the CB2 gene in Japanese alcoholics and depressed subjects. Contrary to the prevailing view that CB2 cannabinoid receptors are restricted to peripheral tissues and predominantly in immune cells, we demonstrated that CB2 cannabinoid receptors and their gene transcripts are widely distributed in the brain. This multifocal expression of iCB2 in the brain suggests that CB2 receptors may play broader roles than previously anticipated and may therefore be exploited as new targets in the treatment of depression and substance abuse.